Nexavar — Generally Well Tolerated

Nexavar chart — Adverse Events Reported

^aHand-foot skin reaction corresponds to palmar plantar erythrodysaesthesis syndrome in MedDRA.

Data from SHARP, a double-blind, randomised, placebo-controlled multicentre, phase III trial that compared Nexavar 400 mg bid (n=299) to placebo (n=303) in patients with HCC. Additional informations about the pivotal study: The SHARP Trial.

Incidence of serious hepatobiliary adverse events (11% vs 9%) were comparable between Nexavar-treated patients and the placebo group¹

Managing skin toxicities

The most common skin irritations were rash and hand-foot skin reaction, which generally appeared during the first 6 weeks of treatment
Management of dermatologic toxicities may include topical therapies for symptomatic relief, temporary treatment interruption, and/or dose modification of Nexavar, or in severe or persistent cases, permanent discontinuation of Nexavar

Suggested dose modifications for skin toxicity

Next: Dosing Information

Term

Explanation for term.